Findings

What do systematic reviews say?

2,545 questions · 2,661 findings · 317 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 608 · 22.8%GRADE not reported 505 · 19%Very low 695 · 26.1%Low 540 · 20.3%Moderate 249 · 9.4%High 64 · 2.4%

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · patients with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 164 participants
Low

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

Change in serum androgen levels · patients with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 184 participants
High

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

Change in BMI · patients with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 136 participants
Moderate

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

Improvement of other clinical signs of hyperandrogenism Acne score ‐ grade 1 to 4 (higher is worse) · patients with hirsutism

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Moderate

Autogenous bone block from the chin + resorbable barrier vs Bovine-derived xenograft (Bio-Oss) plus resorbable barrier

Prosthesis/implant failure (1 year) · Patients with horizontally resorbed maxillary sites needing single implants

Autogenous bone block from the chin + resorbable barrier showed no clear difference in prosthesis/implant failure (1 year) compared with 100% Bio-Oss + resorbable barrier; GRADE not reported.

1 finding from 1 review

Interventions for replacing missing teeth: horizontal and vertical bone augmentation techniques for dental implant… 2009 · Cochrane All outcomes
Up to 1 year post-loading
OR 0.19 [0.01, 4.07]
1 study · 62 participants
GRADE not reported

Prednisone vs placebo or supportive treatment

Persistent kidney disease at any time after treatment · patients with IgAV

Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).

1 finding from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 0.74 [0.42, 1.32]
5 studies · 746 participants
Moderate

Prednisone vs placebo or supportive treatment

Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV

Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).

2 findings from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 0.83 [0.46, 1.52]
4 studies · 655 participants
Moderate
Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 0.98 [0.7, 1.36]
3 studies · 487 participants
High

Prednisone vs placebo or supportive treatment

Children with any continuing kidney disease at 6 months · patients with IgAV

Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).

1 finding from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 0.51 [0.24, 1.11]
3 studies · 379 participants
Moderate

Prednisone vs placebo or supportive treatment

Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV

Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).

2 findings from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 1.06 [0.38, 2.91]
3 studies · 455 participants
Low
Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 1.39 [0.75, 2.59]
2 studies · 287 participants
Moderate

Prednisone vs placebo or supportive treatment

Number developing severe kidney disease · patients with IgAV

Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).

1 finding from 1 review

Interventions for preventing and treating kidney disease in IgA vasculitis 2023 · Cochrane Headline outcomes only
RR 1.58 [0.42, 6]
2 studies · 418 participants
Low

Prednisone vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 1.03 [0.85, 1.24]
1 study · 66 participants
GRADE not reported

Prednisone vs placebo

Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.64 [0.17, 2.45]
1 study · 66 participants
GRADE not reported

Any Psychosocial intervention plus pharm vs pharm standard

Retention in treatment · patients with treatment of opioid dependence

Any Psychosocial intervention plus pharm showed no clear difference in retention in treatment Objective compared with pharm standard (high certainty).

1 finding from 1 review

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of… 2011 · Cochrane Headline outcomes only
RR 1.02 [0.97, 1.07]
26 studies · 2582 participants
High

Any Psychosocial intervention plus pharm vs pharm standard

Opioid abstinence objective · patients with treatment of opioid dependence

Any Psychosocial intervention plus pharm showed no clear difference in opioid abstinence objective compared with pharm standard (high certainty).

1 finding from 1 review

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of… 2011 · Cochrane Headline outcomes only
RR 1.19 [0.91, 1.56]
7 studies · 667 participants
High

Any Psychosocial intervention plus pharm vs pharm standard

Number of participants still in treatment at the end of · patients with treatment of opioid dependence

Any Psychosocial intervention plus pharm showed no clear difference in number of participants still in treatment at the end of compared with pharm standard (high certainty).

1 finding from 1 review

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of… 2011 · Cochrane Headline outcomes only
RR 0.9 [0.77, 1.07]
3 studies · 250 participants
High

Any Psychosocial intervention plus pharm vs pharm standard

Abstinence · patients with treatment of opioid dependence

Any Psychosocial intervention plus pharm showed no clear difference in number of participants abstinent at the end of compared with pharm standard (high certainty).

1 finding from 1 review

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of… 2011 · Cochrane Headline outcomes only
RR 1.15 [0.98, 1.36]
3 studies · 181 participants
High

Any Psychosocial intervention plus pharm vs pharm standard

Compliance · patients with treatment of opioid dependence

1 finding from 1 review

Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of… 2011 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 685 participants
Moderate

Prednisone vs placebo

Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Prednisone showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.71 [0.47, 1.07]
1 study · 66 participants
GRADE not reported

Inlay/interposed bone graft (iliac or Bio-Oss block) + longer implants (vertical augmentation) vs Short implants (8 to 11 mm) without augmentation

Severe pain for > 1 week · Patients with atrophic (resorbed) mandibles needing implants

Inlay/interposed bone graft (iliac or Bio-Oss block) + longer… led to higher severe pain for > 1 week compared with short implants (8 to 11 mm) without augmentation; GRADE not reported.

1 finding from 1 review

Interventions for replacing missing teeth: horizontal and vertical bone augmentation techniques for dental implant… 2009 · Cochrane All outcomes
3 weeks post-surgery
OR 22.67 [4.37, 117.47]
1 study · 40 participants
GRADE not reported

Inlay/interposed bone graft (iliac or Bio-Oss block) + longer implants (vertical augmentation) vs Short implants (8 to 11 mm) without augmentation

Experienced the operation negatively · Patients with atrophic (resorbed) mandibles needing implants

Inlay/interposed bone graft (iliac or Bio-Oss block) + longer… showed no clear difference in experienced the operation negatively compared with short implants (8 to 11 mm) without augmentation; GRADE not reported.

1 finding from 1 review

Interventions for replacing missing teeth: horizontal and vertical bone augmentation techniques for dental implant… 2009 · Cochrane All outcomes
3 weeks post-surgery
OR 3.0 [0.79, 11.44]
1 study · 40 participants
GRADE not reported